{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:04:02Z","timestamp":1790370242030,"version":"4.1.0"},"reference-count":133,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clinthera.2026.09.002","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:33:03Z","timestamp":1790368383000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glucagon-Like Peptide-1 Receptor Agonist-Associated Hepatotoxicity"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8745-6865","authenticated-orcid":false,"given":"Melissa","family":"Palmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.09.002_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2025.100375","article-title":"Obesity: prevalence, causes, consequences, management, preventive strategies and future research directions","volume":"27","author":"Ahmed","year":"2025","journal-title":"Metabol Open"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0002","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(24)02317-1","article-title":"Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants","volume":"404","author":"Zhou","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0003","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"402","author":"Ong","year":"2023","journal-title":"Lancet"},{"issue":"suppl","key":"10.1016\/j.clinthera.2026.09.002_bib0004","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0005","doi-asserted-by":"crossref","first-page":"10383","DOI":"10.2147\/DDDT.S559919","article-title":"The clinical application of GLP-1RAs and GLP-1\/GIP dual receptor agonists based on pharmacological mechanisms: a review","volume":"19","author":"Liu","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0006","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","article-title":"Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis","volume":"64","author":"Armstrong","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0007","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.2337\/db24-0861","article-title":"The GLP-1 receptor agonist dulaglutide attenuates hepatic steatosis in obesity via a weight-independent mechanism","volume":"74","author":"Shantaram","year":"2025","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0008","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0009","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0010","unstructured":"US Food and Drug Administration. FDA approves treatment for serious liver disease known as \u2018MASH\u2019. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-serious-liver-disease-known-mash. Accessed May 30, 2026."},{"key":"10.1016\/j.clinthera.2026.09.002_bib0011","unstructured":"Truveta Research. GLP-1 RA prescription trends: January 2019\u2013March 2026. https:\/\/www.truveta.com\/blog\/research\/glp-1-prescription-trends-january-2019-march-2026\/?utm_campaign=Newsletter&utm_medium=email&_hsenc=p2ANqtz-9dow8Ih-ebfMFXC44beaI7fS4D1RkP9ys4JA3VnLy8J447KrSghFAa_buP_zZdW6Qd_4yBQ8xVMkmtnHPfXtU9XkTnTBtO2qXcxgGB4heQDTk70F8&_hsmi=417181858&utm_content=417181858&utm_source=hs_email. Accessed May 30, 2026."},{"key":"10.1016\/j.clinthera.2026.09.002_bib0012","unstructured":"Pfizer Inc. Pfizer provides update on oral GLP-1 receptor agonist danuglipron. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-provides-update-oral-glp-1-receptor-agonist. Accessed May 30, 2026."},{"key":"10.1016\/j.clinthera.2026.09.002_bib0013","unstructured":"Lovelace B Jr. Pfizer to end development of experimental obesity pill lotiglipron. https:\/\/www.cnbc.com\/2023\/06\/26\/pfizer-to-end-development-of-experimental-obesity-pill-lotiglipron.html. Accessed May 30, 2026."},{"key":"10.1016\/j.clinthera.2026.09.002_bib0014","unstructured":"Terns Pharmaceuticals, Inc. Terns Pharmaceuticals reports topline 12-week data from its Phase 2 trial evaluating oral GLP-1 receptor agonist TERN-601 in obesity. https:\/\/ir.ternspharma.com\/news-releases\/news-release-details\/terns-pharmaceuticals-reports-topline-12-week-data-its-phase-2. Accessed May 30, 2026."},{"key":"10.1016\/j.clinthera.2026.09.002_bib0015","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/clpt.2011.63","article-title":"Drug safety sciences and the bottleneck in drug development","volume":"89","author":"Watkins","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0016","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/1574886314666191004092520","article-title":"Drug withdrawal due to safety: a review of the data supporting withdrawal decision","volume":"15","author":"Craveiro","year":"2020","journal-title":"Curr Drug Saf"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0017","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/hep.32689","article-title":"AASLD practice guidance on drug, herbal, and dietary supplement\u2013induced liver injury","volume":"77","author":"Fontana","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0018","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1056\/NEJMra1816149","article-title":"Drug-induced liver injury \u2013 types and phenotypes","volume":"381","author":"Hoofnagle","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0019","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1055\/s-0029-1240002","article-title":"Epidemiology of idiosyncratic drug-induced liver injury","volume":"29","author":"Bell","year":"2009","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0020","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s40264-021-01051-5","article-title":"Overview of causality assessment for drug-induced liver injury (DILI) in clinical trials","volume":"44","author":"Hey-Hadavi","year":"2021","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0021","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: clinical and research information on drug-induced liver injury. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK547852\/. Accessed May 28, 2026."},{"key":"10.1016\/j.clinthera.2026.09.002_bib0022","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: clinical and research information on drug-induced liver injury. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548392\/. Accessed May 30, 2026."},{"key":"10.1016\/j.clinthera.2026.09.002_bib0023","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0024","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0025","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0026","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.pcd.2025.03.008","article-title":"The promise of tirzepatide: a narrative review of metabolic benefits","volume":"19","author":"Sokary","year":"2025","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0027","unstructured":"Novo Nordisk Inc. Ozempic (semaglutide) injection, for subcutaneous use: prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/209637s020s021lbl.pdf. Accessed May 30, 2026."},{"key":"10.1016\/j.clinthera.2026.09.002_bib0028","unstructured":"Eli Lilly and Company. Mounjaro (tirzepatide) injection, for subcutaneous use: prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215866s000lbl.pdf. Accessed May 30, 2026."},{"key":"10.1016\/j.clinthera.2026.09.002_bib0029","unstructured":"Eli Lilly and Company. Trulicity (dulaglutide) injection, for subcutaneous use: prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/125469s051lbl.pdf. Accessed May 30, 2026."},{"key":"10.1016\/j.clinthera.2026.09.002_bib0030","unstructured":"Novo Nordisk Inc. Victoza (liraglutide) injection, for subcutaneous use: prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/022341s027lbl.pdf. Accessed May 31, 2026."},{"key":"10.1016\/j.clinthera.2026.09.002_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112910","article-title":"Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial","volume":"229","author":"Sklepinski","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"issue":"10_suppl","key":"10.1016\/j.clinthera.2026.09.002_bib0032","doi-asserted-by":"crossref","DOI":"10.1200\/OP.2025.21.10_suppl.528","article-title":"Tirzepatide vs semaglutide for metabolic optimization in patients with cancer: a target trial emulation study","volume":"21","author":"Ashruf","year":"2025","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0033","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2215\/CJN.0000001033","article-title":"Target trial emulation: glucagon-like peptide-1 receptor agonist, sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors for kidney outcome prevention","volume":"21","author":"Hung","year":"2026","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0034","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70367","article-title":"Target trial emulations of GLP-1 and Dual GLP-1\/GIP agonists to reduce major adverse liver outcomes in type 2 diabetes","volume":"45","author":"Henney","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0035","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jamainternmed.2014.674","article-title":"Liraglutide-induced autoimmune hepatitis","volume":"174","author":"Kern","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0036","first-page":"288","article-title":"Liraglutide: unusual drug reaction","volume":"3","author":"Al-Malky","year":"2017","journal-title":"Int J Med Res Prof"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0037","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3390\/biomedicines9020106","article-title":"Liraglutide-induced hepatotoxicity","volume":"9","author":"Maor","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0038","article-title":"An exceedingly rare case of liraglutide-induced liver injury","volume":"2021","author":"Parvataneni","year":"2021","journal-title":"Case Rep Gastrointest Med"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0039","doi-asserted-by":"crossref","first-page":"168","DOI":"10.18053\/jctres.09.202303.004","article-title":"Drug-induced liver injury associated with liraglutide use: a systematic review of detection, severity, causality assessment, and clinical outcomes","volume":"9","author":"Inayat","year":"2023","journal-title":"J Clin Transl Res"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0040","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2174\/0118715303180615231011053011","article-title":"Liraglutide and liver injury: rare case report with literature review","volume":"24","author":"Salehi","year":"2024","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0041","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2023-063719","article-title":"Acute kidney and liver injury associated with low-dose liraglutide in an obese adolescent patient","volume":"154","author":"Komargodski","year":"2024","journal-title":"Pediatrics"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0042","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1159\/000547634","article-title":"Liraglutide-induced liver injury: a case report and review","volume":"19","author":"Lai","year":"2025","journal-title":"Case Rep Gastroenterol"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0043","doi-asserted-by":"crossref","DOI":"10.1097\/MJT.0000000000000826","article-title":"Drug-induced liver injury due to dulaglutide use","volume":"26","author":"Patel","year":"2019","journal-title":"Am J Ther"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0044","doi-asserted-by":"crossref","first-page":"S1189","DOI":"10.14309\/01.ajg.0000785004.17193.b9","article-title":"S2868 Autoimmune hepatitis-like drug injury of the liver associated with the glucagon-like peptide 1 (GLP-1) agonist dulaglutide","volume":"116","author":"Neahusan","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"suppl 1","key":"10.1016\/j.clinthera.2026.09.002_bib0045","article-title":"FRI646 dulaglutide-induced acute liver injury \u2013 a case report","volume":"7","author":"Shahid","year":"2023","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0046","first-page":"674","article-title":"Drug-induced autoimmune-like hepatitis and cholelithiasis associated with dulaglutide and semaglutide use in a young adult: a case report and review of literature","volume":"31","author":"Alghamdi","year":"2024","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0047","doi-asserted-by":"crossref","first-page":"S1141","DOI":"10.14309\/01.ajg.0000784440.97741.d2","article-title":"S2727 The first reported case of drug-induced liver injury caused by semaglutide","volume":"116","author":"Enslin","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0048","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000000922","article-title":"Progressive cholestasis and biliary cirrhosis after initiating oral semaglutide: report from the drug-induced liver injury network","volume":"9","author":"Ma","year":"2022","journal-title":"ACG Case Rep J"},{"issue":"10 S","key":"10.1016\/j.clinthera.2026.09.002_bib0049","doi-asserted-by":"crossref","first-page":"S2370","DOI":"10.14309\/01.ajg.0000964252.91007.e2","article-title":"S3653 Semaglutide-induced hepatotoxicity: a rare case of drug induced liver injury","volume":"118","author":"Galeano Lovera","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0050","doi-asserted-by":"crossref","first-page":"6165","DOI":"10.3748\/wjg.v29.i47.6165","article-title":"Liver decompensation after rapid weight loss from semaglutide in a patient with non-alcoholic steatohepatitis-associated cirrhosis","volume":"29","author":"Peverelle","year":"2023","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0051","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000001776","article-title":"Semaglutide-induced liver injury","volume":"12","author":"Kalsi","year":"2025","journal-title":"ACG Case Rep J"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0052","doi-asserted-by":"crossref","first-page":"omaf177","DOI":"10.1093\/omcr\/omaf177","article-title":"Semaglutide-associated drug-induced liver injury: a case report and review of the literature","volume":"2025","author":"Kempster","year":"2025","journal-title":"Oxf Med Case Rep"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0053","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.70783","article-title":"Semaglutide-induced hepatic injury: a rare case of drug induced liver injury","volume":"13","author":"Kundu","year":"2025","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0054","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.14309\/01.ajg.0001150208.23224.83","article-title":"S5687 hepatotoxicity linked to compounded semaglutide: a rare case of probable drug-induced liver injury","volume":"120","author":"Garg","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0055","doi-asserted-by":"crossref","first-page":"574","DOI":"10.15403\/jgld-5967","article-title":"Idiosyncratic acute liver failure induced by tirzepatide","volume":"33","author":"Terrington","year":"2024","journal-title":"J Gastrointestin Liver Dis"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0056","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1016\/j.cgh.2024.06.025","article-title":"First report of tirzepatide hepatotoxicity with jaundice","volume":"22","author":"Fontana","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0057","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000001484","article-title":"A rare case of tirzepatide-induced hepatotoxicity","volume":"11","author":"Sohal","year":"2024","journal-title":"ACG Case Rep J"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0058","article-title":"Tirzepatide-related acute liver injury","volume":"11","author":"Abdullah","year":"2024","journal-title":"Eur J Case Rep Intern Med"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0059","doi-asserted-by":"crossref","DOI":"10.14309\/crj.0000000000001661","article-title":"Tirzepatide-induced liver injury: a rare medication side effect","volume":"12","author":"Phox","year":"2025","journal-title":"ACG Case Rep J"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0060","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.aed.2025.11.009","article-title":"Tirzepatide-induced liver injury: a rare complication","volume":"13","author":"Spaeth","year":"2025","journal-title":"AACE Endocrinol Diabetes"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0061","article-title":"A rare case of tirzepatide-induced hepatitis: causality assessment with the RUCAM criteria","volume":"4","author":"Ahmed","year":"2025","journal-title":"Ann Intern Med Clin Cases"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0062","doi-asserted-by":"crossref","DOI":"10.1016\/j.ando.2026.102485","article-title":"Acute liver injury associated with tirzepatide: an unexpected adverse event warranting clinical attention","volume":"87","author":"Alqarni","year":"2026","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0063","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2025-269172","article-title":"Drug-induced liver injury secondary to tirzepatide","volume":"19","author":"Cao","year":"2026","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0064","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.14309\/01.ajg.0001150424.12266.b0","article-title":"S5741 fulminant liver failure linked to tirzepatide (mounjaro): a case report and urgent call for vigilance","volume":"120","author":"Mahmoud","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0065","first-page":"949","article-title":"A case of severe cholestatic hepatitis induced by a novel dual agonist of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors","volume":"12","author":"Jiang","year":"2024","journal-title":"J Clin Transl Hepatol"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0066","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","article-title":"Causality assessment of adverse reactions to drugs\u2013I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries","volume":"46","author":"Danan","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0067","unstructured":"Severity Grading In Drug Induced Liver Injury. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548241\/. Accessed May 30, 2026."},{"key":"10.1016\/j.clinthera.2026.09.002_bib0068","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0069","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v6.0 (MedDRA 28.0). July 22 2025. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v6.pdf. Accessed May 30, 2026."},{"key":"10.1016\/j.clinthera.2026.09.002_bib0070","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.mce.2008.11.018","article-title":"Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue","volume":"297","author":"Russell-Jones","year":"2009","journal-title":"Mol Cell Endocrinol"},{"issue":"suppl 1","key":"10.1016\/j.clinthera.2026.09.002_bib0071","first-page":"A164.","article-title":"The molecular basis for the delayed absorption of the once-daily human GLP-1 analogue, liraglutide","volume":"57","author":"Steensgaard","year":"2008","journal-title":"Diabetes."},{"key":"10.1016\/j.clinthera.2026.09.002_bib0072","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1365-2125.2010.03762.x","article-title":"Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide","volume":"70","author":"Flint","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0073","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/apt.12149","article-title":"Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program","volume":"37","author":"Armstrong","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0074","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"Spec Feature","key":"10.1016\/j.clinthera.2026.09.002_bib0075","first-page":"131","article-title":"Trulicity (dulaglutide): a new GLP-1 receptor agonist once-weekly subcutaneous injection approved for the treatment of patients with type 2 diabetes","volume":"8","author":"Fala","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0076","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2147\/DMSO.S134960","article-title":"Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data","volume":"11","author":"Kugler","year":"2018","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0077","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40262-015-0338-3","article-title":"Clinical pharmacokinetics of dulaglutide in patients with type 2 diabetes: analyses of data from clinical trials","volume":"55","author":"Geiser","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0078","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1007\/s00125-020-05265-7","article-title":"Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)","volume":"63","author":"Kuchay","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0079","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1111\/dom.13186","article-title":"Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment","volume":"20","author":"Jensen","year":"2018","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0080","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.clinthera.2020.07.017","article-title":"Oral semaglutide: the first-available noninjectable glucagon-like peptide 1 receptor agonist","volume":"42","author":"Powell","year":"2020","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0081","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/s41573-019-0053-0","article-title":"Advances in oral peptide therapeutics","volume":"19","author":"Drucker","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0082","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2337\/cd22-0118","article-title":"Current understanding of sodium N-(8-[2-hydroxylbenzoyl] amino) caprylate (SNAC) as an absorption enhancer: the oral semaglutide experience","volume":"42","author":"Solis-Herrera","year":"2024","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0083","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jhep.2015.04.016","article-title":"Drug-induced liver injury: interactions between drug properties and host factors","volume":"63","author":"Chen","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0084","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1507\/endocrj.EJ21-0129","article-title":"Comprehensive analysis of the safety of semaglutide in type 2 diabetes: a meta-analysis of the SUSTAIN and PIONEER trials","volume":"68","author":"Yin","year":"2021","journal-title":"Endocr J"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0085","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40262-022-01140-3","article-title":"Effects of hepatic impairment on the pharmacokinetics of the dual GIP and GLP-1 receptor agonist tirzepatide","volume":"61","author":"Urva","year":"2022","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0086","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.2147\/DDDT.S358989","article-title":"Designing a dual GLP-1 R\/GIPR agonist from tirzepatide: comparing residues between tirzepatide, GLP-1, and GIP","volume":"16","author":"Wang","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0087","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.2040-1124.2010.00022.x","article-title":"GIP and GLP-1, the two incretin hormones: similarities and differences","volume":"1","author":"Seino","year":"2010","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0088","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0089","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0090","unstructured":"Soccio R. Zepbound (tirzepatide): clinical review. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/217806Orig1s000MedR.pdf. Accessed May 29, 2026."},{"key":"10.1016\/j.clinthera.2026.09.002_bib0091","doi-asserted-by":"crossref","first-page":"30","DOI":"10.65321\/ntta.2025.002","article-title":"New oral GLP-1 receptor agonists: gliprons","volume":"1","author":"Kim","year":"2025","journal-title":"NeuroTrials"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0092","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.3390\/ijms27031409","article-title":"Orforglipron: a comprehensive review of an oral small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes","volume":"27","author":"Kansakar","year":"2026","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0093","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s41591-021-01391-w","article-title":"Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial","volume":"27","author":"Saxena","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0094","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1111\/dom.15643","article-title":"Once-daily oral small-molecule glucagon-like peptide-1 receptor agonist lotiglipron (PF-07081532) for type 2 diabetes and obesity: two randomized, placebo-controlled, multiple-ascending-dose Phase 1 studies","volume":"26","author":"Buckeridge","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0095","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1111\/dom.16534","article-title":"Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: a randomized, placebo-controlled, dose-ranging phase 2b study","volume":"27","author":"Buckeridge","year":"2025","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0096","unstructured":"FDA Reports Liver Failure in Patient Taking Eli Lilly\u2019s Foundayo. https:\/\/www.barrons.com\/articles\/lilly-foundayo-liver-failure-fda-e1ac5d1c. Accessed May 29, 2026."},{"key":"10.1016\/j.clinthera.2026.09.002_bib0097","unstructured":"Valletti d. As GLP-1 Use Expands, Long-Term Safety Questions Remain Under Watch. https:\/\/www.pharmacytimes.com\/view\/as-glp-1-use-expands-long-term-safety-questions-remain-under-watch. Accessed May 30, 2026."},{"key":"10.1016\/j.clinthera.2026.09.002_bib0098","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMoa2505669","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes","volume":"393","author":"Rosenstock","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0099","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1056\/NEJMoa2511774","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment","volume":"393","author":"Wharton","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0100","unstructured":"Yanoff L. Foundayo NDA approval. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2026\/220934Orig1s000ltr.pdf. Accessed May 30, 2026."},{"key":"10.1016\/j.clinthera.2026.09.002_bib0101","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.2147\/DDDT.S506957","article-title":"A comprehensive review on the pharmacokinetics and drug-drug interactions of approved GLP-1 receptor agonists and a dual GLP-1\/GIP receptor agonist","volume":"19","author":"Min","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0102","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1002\/hep.22895","article-title":"Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex","volume":"49","author":"Lucena","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0103","article-title":"Drug-induced autoimmune-like hepatitis","volume":"23","author":"Garc\u00eda-Cort\u00e9s","year":"2024","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0104","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1210\/jc.2010-2822","article-title":"Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials","volume":"96","author":"Buse","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0105","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/dom.12640","article-title":"Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide","volume":"18","author":"Milicevic","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0106","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1210\/clinem\/dgad532","article-title":"Tirzepatide immunogenicity on pharmacokinetics, efficacy, and safety: analysis of data from phase 3 studies","volume":"109","author":"Mullins","year":"2024","journal-title":"J Clin Endocrinol Metabol"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0107","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.14607","article-title":"Prediction of drug-induced liver injury: from molecular physicochemical properties and scaffold architectures to machine learning approaches","volume":"104","author":"Zhao","year":"2024","journal-title":"Chem Biol Drug Design"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0108","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1046\/j.1463-1326.2001.00159.x","article-title":"Hepatotoxicity of thiazolidinediones","volume":"3","author":"Isley","year":"2001","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0109","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/S0140-6736(99)00569-3","article-title":"Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin","volume":"353","author":"Nakad","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0110","article-title":"Rapid weight loss vs. slow weight loss: which is more effective on body composition and metabolic risk factors?","volume":"15","author":"Ashtary-Larky","year":"2017","journal-title":"Int J Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0111","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1210\/js.2017-00020","article-title":"Effects of rapid weight loss on systemic and adipose tissue inflammation and metabolism in obese postmenopausal women","volume":"1","author":"Alem\u00e1n","year":"2017","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0112","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1572-0241.2006.00419.x","article-title":"Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery","volume":"101","author":"Barker","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0113","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/sj.ijo.0800571","article-title":"Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty","volume":"22","author":"Luyckx","year":"1998","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0114","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2217\/clp.09.85","article-title":"Mechanisms and clinical implications of hepatocyte lipoapoptosis","volume":"5","author":"Cazanave","year":"2010","journal-title":"Clin Lipidol"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0115","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1007\/s11695-017-2925-x","article-title":"Significant liver-related morbidity after bariatric surgery and its reversal-a case series","volume":"28","author":"Eilenberg","year":"2018","journal-title":"Obes Surg"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0116","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70019","article-title":"Drug-induced liver injury in patients with chronic liver disease","volume":"45","author":"Ghabril","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0117","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1053\/j.gastro.2010.04.001","article-title":"Risk factors for idiosyncratic drug-induced liver injury","volume":"138","author":"Chalasani","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0118","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1097\/HEP.0000000000001281","article-title":"Assessment of liver injury potential of investigational medicines in drug development","volume":"84","author":"Chalasani","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0119","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S2213-8587(20)30074-7","article-title":"Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3 a trial","volume":"8","author":"Yabe","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0120","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0140-6736(23)01127-3","article-title":"Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial","volume":"402","author":"Aroda","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0121","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0122","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamainternmed.2025.3599","article-title":"Oral semaglutide in an East Asian population with overweight or obesity, with or without type 2 diabetes: the OASIS 2 randomized clinical trial","volume":"185","author":"Kadowaki","year":"2025","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0123","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1613610","article-title":"Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis","volume":"16","author":"Xie","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0124","doi-asserted-by":"crossref","DOI":"10.1177\/20420188251406456","article-title":"GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications","volume":"16","author":"Ram\u00edrez-Mej\u00eda","year":"2025","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0125","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1097\/00042737-200012120-00015","article-title":"Gallstones in obesity and weight loss","volume":"12","author":"Erlinger","year":"2000","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"10.1016\/j.clinthera.2026.09.002_bib0126","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1381\/096089203322190862","article-title":"Impact of rapid weight reduction on risk of cholelithiasis after bariatric surgery","volume":"13","author":"Igl\u00e9zias Brand\u00e3o de Oliveira","year":"2003","journal-title":"Obes Surg"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0127","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Int Med"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0128","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1053\/j.gastro.2025.06.003","article-title":"Glucagon-like peptide-1 receptor agonists and gastrointestinal adverse events: a systematic review and meta-analysis","volume":"169","author":"Chiang","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0129","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2217\/pgs.12.45","article-title":"Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here?","volume":"13","author":"Urban","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0130","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1111\/jdi.70087","article-title":"Genetic analysis of the correlation between GLP1 action and metabolic liver disease: insights from Mendelian randomization analysis","volume":"16","author":"Ma","year":"2025","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0131","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175356","article-title":"Pharmacogenomics of GLP-1 receptor agonists: focus on pharmacological profile","volume":"936","author":"Jakhar","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.clinthera.2026.09.002_bib0132","unstructured":"FDA. FDA\u2019s concerns with unapproved GLP-1 drugs used for weight loss. https:\/\/www.fda.gov\/drugs\/drug-alerts-and-statements\/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss. Accessed May 30, 2026."},{"key":"10.1016\/j.clinthera.2026.09.002_bib0133","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s11606-025-09765-3","article-title":"Compounded GLP-1 receptor agonists: opportunity for compassionate conversation","volume":"41","author":"Chetty","year":"2026","journal-title":"J Gen Intern Med"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826003401?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826003401?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:33:22Z","timestamp":1790368402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826003401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":133,"alternative-id":["S0149291826003401"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.09.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-Like Peptide-1 Receptor Agonist-Associated Hepatotoxicity","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}